Articles from Fortis Life Sciences

Grant program expands access to advanced single-domain antibody technologies to support the research and development of next-generation therapies

Abcore®, a brand operating within the Antibody Solutions (AbS) business division as a part of Fortis Life Sciences®, an innovation leader in VHH discovery and single-domain-antibody library construction, announces the launch of AbNano™ Anti-T-Cell VHH Library, strengthening its VHH platform solutions. The Anti-T-Cell Library builds on the success of Abcore’s previously released AbNano™ Naïve VHH Library and expands innovative capabilities in immunology-focused research discovery.

Fortis Life Sciences, a provider of high-quality reagents and custom services for discovery, development, and manufacturing, has expanded its international presence by opening an office in Seoul, South Korea.

Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced it is the exclusive channel partner for AccuGenomics in the Unites States, with co-exclusive rights in Europe. Under the agreement, Fortis will help expand customer access to AccuGenomics’ patented SNAQ™-SEQ Internal Standards technology, the only commercial internal standards for next-generation sequencing (NGS).

Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced highlights from its first year of operations. Fortis delivered strong financial performance in 2021 and has significantly scaled its commercial capabilities. Over the course of the last thirteen months, the company has built a portfolio of high-quality products and brands serving attractive end markets including diagnostic, therapeutic and discovery, through its acquisition of four complementary companies: